Lymphomagenesis
Novel pathogenetic mechanisms and therapeutic targets in B cell lymphomas
R. Dalla Favera
Reversing hematopoietic tumorigenesis through oncogene inactivation
D.W. Felsher
Modeling human mature B cell lymphomas with constitutive NFkB activity in the mouse
M. Schmidt-Supprian, Y. Sasaki, K. Rajewsky
Chronic Lymphocytic Leukemia
miR genes in lymphoid malignancies
C. Croce
How close are we to curing chronic lymphocytic leukemia?
M.J. Keating
Molecular targets
Targeting transcriptional repression in diffuse large B-cell lymphoma
A.M. Melnick
Genomic scale RNA interference screens to reveal the Achille’s heel of cancer
L. Staudt
LRF/Pokemon plays a critical role in B versus T lymphoid lineage fate decision
T. Maeda, T. Merghoub, L. Dong, R.M. Hobbs, M. Maeda, J. Zakrzewski, M. van den Brink, A. Zelent, H. Shigematsu, K. Akashi, J. Teruya-Feldstein, G. Cattoretti, P.P. Pandolfi
Diffuse large cell lymphoma
Aberrant somatic hypermutation in the pathogenesis of diffuse large B-cell lymphoma
L. Pasqualucci
Optimizing treatment for diffuse large B-cell lymphoma
N. Schmitz, M. Nickelsen
Impact of radioimmunotherapy on aggressive of non-Hodgkin’s lymphoma
P.L. Zinzani
T- cell lymphoma
Validation of the anaplastic large cell lymphoma signature
R. Piva, E. Pellegrino, L. Agnelli, A. Neri, R. Chiarle, G. Palestro, G. Inghirami
Novel drugs for the treatment of T-cell lymphoma
O. O’Connor
Hodgkin’s Lymphoma
Pathogenesis of Hodgkin’s lymphoma
R. Küppers
Best treatment options for Hodgkin’s disease
H. Bredenfeld
New therapy for Hodgkin’s lymphoma
A. Younes
Infection-associated Lymphoma
Seizing of T cells by human T-cell leukemia/lymphoma virus type 1
G. Franchini
Management of HIV-related lymphoma in HAART era
M. Spina
HCV and non-Hodgkin’s lymphoma: epidemiology, biology and therapy
G. Pozzato
Late Breaking News
Infusion of cytokine induced killer cells in patients relapsed after allogeneic transplantation
A. Rambaldi, M. Introna
Demonstration of donor ID-specific CD8 and CD4 responses after allogeneic transplantation – in vivo demonstration of GVL
R. Le Dieu, J. Gribben
Apoptosis as Target
Understanding, diagnosing, and targeting BCL-2 addiction
A. Letai
TRAIL-armed CD34+ cells as systemic vehicles of cancer gene therapy
A.M. Gianni
Mapatumumab (agonistic human monoclonal antibody 10 to TRAIL receptor-1): review of in vitro and in vivo anti-lymphoma activity
M.S. Czuczman, F.J. Hernandez-Ilizaliturri, J. Vose,
A.D. Zelenetz, M.R. Smith, H. Burris, S. Ansell,
J. Klein, E. Kumm, G. Gallant, A. Younes
Monoclonal Antibodies
The role of intensive chemo-immunotherapy in optimizing treatment for high-risk lymphoma
C. Tarella, M. Zanni, A. Rambaldi, M. Magni, F. Benedetti, C. Patti, F. Ciceri, A. Gallamini, S. Cortelazzo, I. Majolino, R. Passera, R. Rosato, S. Mirto, M. Boccadoro, D. Caracciolo, M. Di Nicola, P. Corradini, G. Pizzolo, T. Barbui, A.M. Gianni